Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 202212
Company: CIPLA LIMITED
Company: CIPLA LIMITED
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
NEVIRAPINE | NEVIRAPINE | 50MG | TABLET, FOR SUSPENSION; ORAL | None (Tentative Approval) | None | No | No |
NEVIRAPINE | NEVIRAPINE | 100MG | TABLET, FOR SUSPENSION; ORAL | None (Tentative Approval) | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
04/30/2012 | ORIG-1 | Tentative Approval | Type 5 - New Formulation or New Manufacturer | STANDARD |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202212Orig1s000ltr.pdf |